Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 11 (6), 749-57

Long-acting Hormonal Contraception

Affiliations
Review

Long-acting Hormonal Contraception

Giuseppe Benagiano et al. Womens Health (Lond).

Abstract

Today, a new category of fertility-regulating agents has been created: long-acting, reversible hormonal contraceptives; they minimize compliance, while maximize effectiveness. They comprise subdermal implants and intrauterine devices. Other long-acting agents exist, such as Depo Provera and Noristerat. Use of Depo Provera and Noristerat carries great effectiveness, good clinical safety and usefulness in developing countries. They cause no significant increase in breast cancer risk, but they may carry an increased risk of HIV. Subcutaneous delivery systems have two common features: prolongation of effect is obtained by a drug reservoir and for most of their duration of action they provide a continuous, sustained release of the active hormone. Finally, the intrauterine system Mirena represents both a very effective contraceptive and a specific treatment for menorrhagia.

Keywords: Depot–Depo Provera; Implanon; Jadelle; Mirena; Noristerat; Uniplant; injectable contraceptives; intrauterine contraceptive systems; long-acting contraceptives; subcutaneous contraceptive implants.

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

MeSH terms

Substances

LinkOut - more resources

Feedback